ACI
ADVM

AMP Capital Investors’s Adverum Biotechnologies ADVM Stock Holding History

AMP Capital Investors’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,440
Closed -$150K – 1249
2020
Q3 		$150K Buy
+1,440
New +$216K ﹤0.01% 1185

Other funds holding ADVM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

AMP Capital Investors's ADVM Position: Q4 2020 in Review

AMP Capital Investors sold out of Adverum Biotechnologies (ADVM) in Q4 2020, closing a stake of 1,440 shares — an estimated $150K sold.

AMP Capital Investors first reported a position in ADVM in Q3 2020 and held it in 1 quarter. The position peaked at $150K in Q3 2020. 155 funds tracked by Wall St. Rank hold ADVM as of Q4 2020.

  • AMP Capital Investors reported no remaining Adverum Biotechnologies position as of Q4 2020 after selling out during the quarter.
  • AMP Capital Investors sold 1,440 Adverum Biotechnologies shares in Q4 2020, an estimated $150K.
  • AMP Capital Investors first reported a position in Adverum Biotechnologies in Q3 2020 and held it in 1 quarter.
  • AMP Capital Investors's Adverum Biotechnologies position peaked at $150K in Q3 2020.
  • 155 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2020.

Based on AMP Capital Investors's 13F filing for Q4 2020, filed 12 Feb 2021.